4F-MDMB-BINACA

Leave a Comment / Indole based / By

Summary

4F-MDMB-BINACA, also recognized as 4F-MDMB-BUTINACA or 4F-ADB, belongs to the indazole-3-carboxamide family and is classified as a synthetic cannabinoid. This compound has been utilized as an active component in synthetic cannabis products and has been available as a designer drug since late 2018. It acts as an agonist for the CB1 receptor, with an EC50 value of 7.39 nM, although its selectivity remains uncertain. Notably, in December 2019, the United Nations Office on Drugs and Crime (UNODC) introduced scheduling recommendations to categorize 4F-MDMB-BINACA as a Schedule II substance worldwide.

Identifiers
IUPAC name
CAS Number2390036-46-9
PubChem CID145707216
ChemSpider71117201
UNIIZH38UTM145
Chemical and physical data
FormulaC19H26FN3O3
Molar mass363.433 g·mol−1

Legal Status

United Kingdom:
Under the Psychoactive Substances Act 2016, the sale, distribution, supply, transportation, or trade of this pharmaceutical drug is illegal.
United States:
The DEA (Drug Enforcement Administration) has issued a notice of intent to temporarily classify 4F-MDMB-BUTICA as Schedule I, effective on or after May 4, 2023. This temporary status may last up to two years, during which the DEA could pursue permanent scheduling. If the DEA fails to file for permanent placement by May 4, 2025, the temporary Schedule I classification will expire.
North Dakota:
As of April 27, 2023, 4F-MDMB-BINACA has been categorized as a Schedule I substance in North Dakota.

FAQ

1. What is 4F-MDMB-BINACA?

  • 4F-MDMB-BINACA is a synthetic cannabinoid belonging to the indazole-3-carboxamide family. It has been utilized as an active ingredient in synthetic cannabis products and is known by other names like 4F-MDMB-BUTINACA or 4F-ADB.

2. When did 4F-MDMB-BINACA become available as a designer drug?

  • 4F-MDMB-BINACA has been sold as a designer drug since late 2018.

3. How does 4F-MDMB-BINACA affect the body?

  • 4F-MDMB-BINACA is an agonist of the CB1 receptor. This means it can interact with the CB1 receptor in the endocannabinoid system, potentially leading to various effects, although the selectivity for this target is not entirely clear.

4. What is the legal status of 4F-MDMB-BINACA in the United Kingdom?

  • In the United Kingdom, it is illegal to sell, distribute, supply, transport, or trade 4F-MDMB-BINACA under the Psychoactive Substances Act 2016.

5. What is the status of 4F-MDMB-BUTICA in the United States?

  • The DEA (Drug Enforcement Administration) has announced its intent to temporarily classify 4F-MDMB-BUTICA as Schedule I, starting on or after May 4, 2023. This temporary classification may last for up to two years, with the possibility of the DEA pursuing permanent scheduling.

6. What about the legal status of 4F-MDMB-BINACA in North Dakota?

  • North Dakota has placed 4F-MDMB-BINACA into Schedule I as of April 27, 2023.

7. Is the use of 4F-MDMB-BINACA considered safe?

  • The safety of using 4F-MDMB-BINACA is uncertain, and it may pose health risks. Designer drugs and synthetic cannabinoids can have unpredictable effects, making their use potentially dangerous.

8. Can 4F-MDMB-BINACA be detected in drug tests?

  • The ability to detect 4F-MDMB-BINACA in drug tests may depend on the specific tests used and their sensitivity to this substance.

9. Where can I find more information about 4F-MDMB-BINACA and its effects?

  • For detailed information on 4F-MDMB-BINACA, its properties, legal status, and potential health risks, consult reputable sources such as government health agencies, medical professionals, and substance abuse organizations.

References

  1. As of July 24, 2023, the Anvisa (Agência Nacional de Vigilância Sanitária) published the “RDC Nº 804 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial,” which translates to “Collegiate Board Resolution No. 804 – Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control” in Brazilian Portuguese. This resolution pertains to the regulation of controlled substances.
  2. In a September 2019 study conducted by Krotulski AJ, Mohr AL, Kacinko SL, and colleagues, titled “4F-MDMB-BINACA: A New Synthetic Cannabinoid Widely Implicated in Forensic Casework,” the synthetic cannabinoid 4F-MDMB-BINACA was extensively examined in the context of forensic casework. The study was published in the Journal of Forensic Sciences, Volume 64, Issue 5, spanning pages 1451 to 1461, and is accessible via doi:10.1111/1556-4029.14101. The PMID is 31260580, and S2CID is 195770459.
  3. In December 2022, a research paper authored by Tokarczyk B, Jurczyk A, Krupińska J, and Adamowicz P titled “Fatal intoxication with new synthetic cannabinoids 5F-MDMB-PICA and 4F-MDMB-BINACA-parent compounds and metabolite identification in blood, urine and cerebrospinal fluid” was published in Forensic Science, Medicine, and Pathology, Volume 18, Issue 4. This research delves into the identification of parent compounds and metabolites in cases of fatal intoxication involving synthetic cannabinoids. You can access this study via doi:10.1007/s12024-022-00492-3. The study is also available in PMC with reference to PMC 9194349, and the PMID is 35699867.
  4. In October 2022, Wagmann L, Stiller RG, Fischmann S, Westphal F, and Meyer MR conducted research on the toxicokinetics of synthetic cannabinoids. Their study, titled “Going deeper into the toxicokinetics of synthetic cannabinoids: in vitro contribution of human carboxylesterases,” was published in Archives of Toxicology, Volume 96, Issue 10, covering pages 2755 to 2766. You can find the study via doi:10.1007/s00204-022-03332-z. It is also available in PMC with reference to PMC 9352624, and the PMID is 35788413.
  5. A December 2020 study by Cannaert A, Sparkes E, Pike E, and others delved into the synthesis and in vitro cannabinoid receptor 1 activity of various synthetic cannabinoids, including 4F-MDMB-BINACA. This study was published in ACS Chemical Neuroscience, Volume 11, Issue 24, covering pages 4434 to 4446. It is accessible via doi:10.1021/acschemneuro.0c00644. The PMID is 33253529, and S2CID is 227246346.
  6. Detailed information about 4F-MDMB-BINACA can be found in a document retrieved on April 15, 2023.
  7. In December 2019, the World Health Organization (WHO) made recommendations regarding the scheduling of new psychoactive substances (NPS).
  8. The Hungarian Institute for Forensic Sciences provided analytical data for 4F-MDMB-BICA on May 28, 2020.
  9. On April 4, 2023, the Federal Register published information regarding the temporary placement of several substances, including MDMB-4en-PINACA, 4F-MDMB-BUTICA, ADB-4en-PINACA, CUMYL-PEGACLONE, 5F-EDMB-PICA, and MMB-FUBICA, in Schedule I.
  10. On January 3, 2023, the Sixty-eighth Legislative Assembly of North Dakota introduced an act amending and reenacting sections of the North Dakota Century Code concerning the scheduling of controlled substances.

Leave a Comment

Your email address will not be published. Required fields are marked *